Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9714258 | BRISTOL | Diaryl macrocycles as modulators of protein kinases |
Jan, 2035
(10 years from now) | |
US10294242 | BRISTOL | Diaryl macrocycle polymorph |
Jul, 2036
(12 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11452725 | BRISTOL | Chiral diaryl macrocycles and uses thereof |
Jul, 2036
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 15, 2030 |
Drugs and Companies using REPOTRECTINIB ingredient
Market Authorisation Date: 15 November, 2023
Treatment: Treatment of adult patients with locally advanced or metastatic ros1-positive non-small cell lung cancer (nsclc)
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9181200 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9585883 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 28, 2029 |
New Chemical Entity Exclusivity (NCE) | Apr 28, 2027 |
M (M) | Jun 15, 2026 |
Drugs and Companies using MAVACAMTEN ingredient
NCE-1 date: 2026-04-28
Market Authorisation Date: 28 April, 2022
Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11571436 | BRISTOL | NA |
May, 2029
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 1, 2027 |
Drugs and Companies using AZACITIDINE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10000480 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(9 years from now) | |
USRE47929 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
Nov, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11021475 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 9, 2027 |
Drugs and Companies using DEUCRAVACITINIB ingredient
NCE-1 date: 2026-09-09
Market Authorisation Date: 09 September, 2022
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are canididates for systemic therapy or phototherapy
Dosage: TABLET;ORAL